Tickertape - Financial freedom begins here

Bajaj Finserv Ltd, Tanla Platforms Ltd, One 97 Communications Ltd, Mahindra & Mahindra Financial Services Ltd are among the other stocks to see a surge in volumes on BSE today, 27 April 2026.India Cements Ltd notched up volume of 3.52 lakh shares by 10:47 IST on BSE, a 35.17 fold spurt over two-week average daily volume of 10006 shares. The stock rose 14.77% to Rs.467.90. Volumes stood at 11417 shares in the last session.Bajaj Finserv Ltd saw volume of 20.98 lakh shares by 10:47 IST on BSE, a 27.05 fold spurt over two-week average daily volume of 77539 shares. The stock increased 0.20% to Rs.1,773.90. Volumes stood at 9470 shares in the last session.Tanla Platforms Ltd saw volume of 4.09 lakh shares by 10:47 IST on BSE, a 13.71 fold spurt over two-week average daily volume of 29828 shares. The stock increased 10.87% to Rs.539.25. Volumes stood at 44697 shares in the last session.One 97 Communications Ltd recorded volume of 8.9 lakh shares by 10:47 IST on BSE, a 12.15 times surge over two-week average daily volume of 73202 shares. The stock lost 3.84% to Rs.1,103.00. Volumes stood at 73001 shares in the last session.Mahindra & Mahindra Financial Services Ltd notched up volume of 13.64 lakh shares by 10:47 IST on BSE, a 9.1 fold spurt over two-week average daily volume of 1.50 lakh shares. The stock rose 7.66% to Rs.316.85. Volumes stood at 99569 shares in the last session.

On year on year (YoY) basis, the company's consolidated net profit jumped 14.5% and revenue from operations clmbed 15% in Q4 FY26. Profit before tax (PBT) stood at Rs 166.65 crore in Q4 FY26, up 14.2% YoY. In Q4 FY26, EBITDA jumped 17.3% YoY to Rs 192 crore, while EBITDA margin improved to 16.3% from 16% in Q4 FY25. During the quarter, revenue from digital platform segment jumped 9.8% YoY to Rs 103 crore while revenue from enterprise comomunications stood at Rs 1,074.6 crore, up 15.5% YoY. Free cash flow stood at Rs 206 crore in the quarter ended 31st March 2026, translating to 154% of PAT, reflecting strong cash conversion. On annual basis, the company's consolidated net profit rose 0.4% marginally to Rs 509.15 crore in FY26 compared with Rs 507.28 crore in FY25. Revenue from operations increased 9.7% to Rs 4,417.71 crore in FY26 compared with Rs 4,027.72 crore recorded in the previous fiscal. Meanwhile, the company has declared a 2nd interim dividend of Rs 6 per equity share of face value of Re 1 each for FY26. The record date for the dividend payment has been fixed as 30 April 2026. Hyderabad-based Tanla Platforms is an AI-native SaaS company focused on enabling secure and scalable digital communications for enterprises and users. The company works closely with leading telecom operators to strengthen data security, privacy, and protection against spam and fraud, and serves over 2,500 enterprises across sectors, including global technology companies such as Google, Meta and Truecaller.

According to the company's exchange filing, Sun Pharma would acquire 100% of Organon's issued and outstanding shares for cash at a price of $14 per share, aggregating to approximately $3.99 billion in total equity value. The company plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The transaction is expected to close in early 2027. Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women's health, the company's portfolio includes more than 70 products across Women's Health and General Medicines, which includes biosimilars, commercialized across 140 countries, with the U.S., Europe, China, Canada, and Brazil among its largest markets. This global footprint is supported by six manufacturing facilities across the European Union and emerging markets, reinforcing its scale and reach. The proposed acquisition of Organon is aligned with Sun Pharma's strategy of growing its Innovative Medicines business. The combined company becomes a stronger player in Established Brands /Branded Generics business. The deal also enables Sun Pharma's entry into biosimilars as a Top-10 global player. Organon's portfolio, global footprint and strong stakeholder relationships shall complement Sun Pharma's existing strengths and enhance long term value creation. The combined entity would be among the top 25 global pharmaceutical companies with combined revenue of $12.4 billion. It would also become a stronger cash generating company with EBITDA and cash flow set to nearly double, supporting deleveraging from post transaction net debt-to-EBITDA of 2.3 times. The transaction has been approved by the boards of directors of Sun Pharma and Organon and is subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders. Dilip Shanghvi, executive chairman of Sun Pharma, said: 'Organon's portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.' Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. The company has reported a 16.03% rise in consolidated net profit to Rs 3,368.81 crore on a 13.49% increase in revenue to Rs 15,520.54 crore in Q3 FY26 over Q3 FY25.

UCO Bank announced that the Board of Directors of the Company at its meeting held on 25 April 2026, inter alia, have recommended the final dividend of Rs 0.44 per equity Share (i.e. 4.4%) , subject to the approval of the shareholders.

Axis Bank announced that the 32nd Annual General Meeting(AGM) of the bank will be held on 31 July 2026.

Meesho will hold a meeting of the Board of Directors of the Company on 6 May 2026.

The headline equity indices traded with substantial gains in morning trade, with the Nifty 50 trading above the 24,000 level. Pharma shares rallied after declining in the previous trading session. At 10:30 IST, the barometer index, the S&P BSE Sensex rallied 423.13 points or 0.55% to 77,087.69. The Nifty 50 index advanced 128.40 points or 0.54% to 24,026.35. In the broader market, the BSE 150 MidCap Index jumped 1.15% and the BSE 250 SmallCap Index surged 1.68%. The market breadth was strong. On the BSE, 2,905 shares rose and 952 shares fell. A total of 233 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, dropped 4.14% to 18.90. Earnings Today: Varun Beverages (up 1.07%), Coal India (up 0.56%), Adani Total Gas (up 1.03%), AU Small Finance Bank (down 2.93%), Aye Finance (up 2.75%), Bajaj Housing Finance (up 1.72%), Canara Robeco Asset Management Company (up 2.12%), Agi Greenpac (up 2.49%), Astec Lifesciences (up 0.27%), City Union Bank (up 1.39%), Prataap Snacks (down 0.33%), Huhtamaki India (up 1.56%), Jindal Saw (up 2.75%), Kirloskar Pneumatic Company (up 3.14%), Mahindra Holidays & Resorts India (up 2.42%), Nippon Life India Asset Management (up 0.47%), The Phoenix Mills (up 0.66%), Piramal Finance (down 1.23%), Punjab & Sind Bank (up 1.33%), Rallis India (up 0.96%), Rossari Biotech (up 0.33%), SBI Cards and Payment Services (up 0.63%), Supreme Industries (up 1.96%), Tamilnad Mercantile Bank (up 2.88%), UltraTech Cement (up 1.02%), Unicommerce Esolutions (up 3.55%) and Websol Energy System (up 2.69%) will declare their results later today. Buzzing Index: The Nifty Pharma index jumped 2.71% to 23,193. The index fell 1.77% in the past trading session. Sun Pharmaceutical Industries (up 7.65%), Alkem Laboratories (up 3.11%), Gland Pharma (up 2.42%), Zydus Lifesciences (up 2.40%), Divis Laboratories (up 2.04%), Cipla (up 1.74%), Torrent Pharmaceuticals (up 1.60%), Ajanta Pharma (up 1.57%), Lupin (up 1.45%) and J B Chemicals & Pharmaceuticals (up 1.40%) advanced. Stocks in Spotlight: Atul Auto gained 6.03% after the company entered into a memorandum of understanding (MoU) with Exponent Energy to manufacture and supply 15,000 electric three-wheelers integrated with the latter's battery system and powertrain. UTI Asset Management Company (UTI AMC) tumbled 5.21% after the AMC reported a consolidated net loss of Rs 67 crore in Q4 FY26 as against a net profit of Rs 87 crore in Q4 FY25. Cyient declined 1.85% after the company reported a 32.61% fall in consolidated net profit to Rs 65.5 crore despite a 3.94% rise in total income to Rs 1,953.5 crore in Q4 FY26 over Q3 FY26.

Net profit of Sejal Glass rose 198.94% to Rs 11.33 crore in the quarter ended March 2026 as against Rs 3.79 crore during the previous quarter ended March 2025. Sales rose 69.48% to Rs 114.55 crore in the quarter ended March 2026 as against Rs 67.59 crore during the previous quarter ended March 2025. For the full year,net profit rose 162.23% to Rs 28.74 crore in the year ended March 2026 as against Rs 10.96 crore during the previous year ended March 2025. Sales rose 62.78% to Rs 396.50 crore in the year ended March 2026 as against Rs 243.58 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales114.5567.59 69 396.50243.58 63 OPM %15.8713.91 -15.5013.94 - PBDT16.725.73 192 46.9819.09 146 PBT12.253.78 224 31.6211.64 172 NP11.333.79 199 28.7410.96 162 Powered by Capital Market - Live

Net profit of Avantel declined 21.55% to Rs 4.77 crore in the quarter ended March 2026 as against Rs 6.08 crore during the previous quarter ended March 2025. Sales rose 29.58% to Rs 63.83 crore in the quarter ended March 2026 as against Rs 49.26 crore during the previous quarter ended March 2025. For the full year,net profit declined 73.44% to Rs 14.99 crore in the year ended March 2026 as against Rs 56.44 crore during the previous year ended March 2025. Sales declined 10.54% to Rs 222.87 crore in the year ended March 2026 as against Rs 249.13 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales63.8349.26 30 222.87249.13 -11 OPM %21.2923.57 -21.4837.13 - PBDT12.8811.43 13 44.7191.24 -51 PBT7.328.49 -14 24.6479.44 -69 NP4.776.08 -22 14.9956.44 -73 Powered by Capital Market - Live

The company reported profit before exceptional items and tax of Rs 232.11 crore in Q4 FY26, compared with Rs 142.89 crore in Q4 FY25. The firm reported an exceptional item of Rs 2.88 crore during the quarter. Total EBITDA jumped 61.4% to Rs 263.8 crore in Q4 FY26, compared with Rs 163.4 crore in Q4 FY25. Total EBITDA margin improved by 602 basis points (bps) to 16.51% in Q4 FY26, compared with 10.49% in Q4 FY25. Total sales volume of the company's manufactured products increased by 5.4% in Q4 FY26 to 100,664 MT from 95,556 MT in Q4 FY25. On a full-year basis, the company's standalone net profit fell 16.19% YoY to Rs 327.31 crore, while revenue declined 11.37% YoY to Rs 5,338.40 crore in FY26 compared with FY25. Meanwhile, the board has recommended a final dividend of Rs 8 per equity share for FY26, subject to shareholders' approval at the AGM. Shareholders on record as of 14 July 2026 will be eligible, and the dividend will be paid on or after 1 August 2026. Supreme Petrochem (SPL) is engaged in the styrenics business and manufactures polystyrene (PS), expandable polystyrene (EPS), masterbatches and compounds of styrenics and other polymers, as well as extruded polystyrene insulation boards (XPS). The company's manufacturing facilities are located in Amdoshi, District Raigad, Maharashtra, and Manali New Town, Chennai, Tamil Nadu. Shares of Supreme Petrochem declined 5.50% to Rs 768.65 on the BSE.